Michael Barbella, Managing Editor06.02.22
Exactech has been awarded a new U.S. patent for the Newton Knee, its platform of cutting-edge technology designed to provide optimal implant balance in a reproducible way.
“The patent allowance supports the uniqueness of Newton and its ability to maintain a force-controlled environment regardless of the joint gap through antagonist sub-mechanisms,” said Laurent Angibaud, vice president of Advanced Surgical Technologies at Exactech. “While initially dedicated to total knee arthroplasty, Newton has the potential to be applied to other joints where proper soft tissue management is of paramount importance.”
Patent No. 11,278,338 recognizes Newton’s approach to providing critical soft tissue data that helps orthopedic surgeons precisely execute a total knee replacement. Newton captures active balance data through the entire arc of motion with the patella in place and seamlessly integrates with ExactechGPS to allow surgeons the ability to visualize a predictive plan through quantifiable insights. This results in a system that is designed for a dynamic, patient-specific and reproducible outcome.
“This recognition is a significant achievement for Exactech,” said Darin Johnson, Exactech president and CEO. “The patent not only protects the commercial potential of the Newton Knee, but it also demonstrates our unwavering commitment to protecting innovation around our entire Active Intelligence suite of technologies.”
The Newton Knee is in pilot release with limited launch planned for later this year.
Exactech is a global medical device company that develops and markets orthopedic implant devices, related surgical instruments and the Active Intelligence platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia, and the Pacific.
“The patent allowance supports the uniqueness of Newton and its ability to maintain a force-controlled environment regardless of the joint gap through antagonist sub-mechanisms,” said Laurent Angibaud, vice president of Advanced Surgical Technologies at Exactech. “While initially dedicated to total knee arthroplasty, Newton has the potential to be applied to other joints where proper soft tissue management is of paramount importance.”
Patent No. 11,278,338 recognizes Newton’s approach to providing critical soft tissue data that helps orthopedic surgeons precisely execute a total knee replacement. Newton captures active balance data through the entire arc of motion with the patella in place and seamlessly integrates with ExactechGPS to allow surgeons the ability to visualize a predictive plan through quantifiable insights. This results in a system that is designed for a dynamic, patient-specific and reproducible outcome.
“This recognition is a significant achievement for Exactech,” said Darin Johnson, Exactech president and CEO. “The patent not only protects the commercial potential of the Newton Knee, but it also demonstrates our unwavering commitment to protecting innovation around our entire Active Intelligence suite of technologies.”
The Newton Knee is in pilot release with limited launch planned for later this year.
Exactech is a global medical device company that develops and markets orthopedic implant devices, related surgical instruments and the Active Intelligence platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia, and the Pacific.